Get all your news in one place.
100's of premium titles.
One app.
Start reading
The Economic Times
The Economic Times
National

Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal

Eli Lilly ​will buy AtaiBeckley for up ​to $3.8 billion, the company said on Thursday, joining a ​race among pharma majors to develop psychedelic treatments for depression and other mental health disorders.

Interest in the sector received a boost after U.S. President Donald Trump in ‌April directed ⁠health ⁠regulators to speed up reviews of certain psychedelic treatments and increased federal funding for research ​in the field.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.